<DOC>
	<DOCNO>NCT02686216</DOCNO>
	<brief_summary>Biodistribution , pharmacokinetics , safety F-18 THK-5351 PET Alzheimer 's disease patient healthy subject .</brief_summary>
	<brief_title>Biodistribution , Pharmacokinetics , Safety F-18 THK-5351 PET Alzheimer 's Disease Patients Healthy Subjects . ( Positron Emission Tomograph )</brief_title>
	<detailed_description>Totally 24 subject age 20-90 include 12 healthy cognitively intact subject 12 probably Alzheimer 's dementia patient NINCDS-ADRDA criterion . For disease subject , caregiver able report activity daily live mental status . Patient able give inform consent caregiver give consent subject assent .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Healthy Neurologic test . ( MMSE 2430 , Wechsler Logical Memory score &gt; 5 ) . Subjects must provide write inform consent . Patients AD Diagnosis AD accord clinical diagnostic criterion `` possible AD '' NINCDSADRDA criterion MMSE 2026 , Clinical dementia rating 0.5 1 , Wechsler Logical Memory score &lt; =4 Patient provide write informed consent prior study entry . ( If patient incapable informed consent , caregiver may consent behalf patient . The caregiver able report activity daily live mental status . ) Pregnant become pregnant Current breast feeding Clinically significant abnormal laboratory value Unstable medical psychiatric illness . Cardiovascular disease ( cardiac surgery myocardial infarction within last 6 month ; unstable angina ; decompensated congestive heart failure ; significant cardiac arrhythmia ; congenital heart disease ) . History drug alcohol abuse within last year , prior prolonged history abuse . History severe allergic anaphylactic reaction particularly test drug . PI assessment high risk .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>F-18 THK-5351 PET</keyword>
</DOC>